Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

154.00 -0.98 (-0.63%)

Streaming Delayed Price Updated: 10:18 AM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

51 52 Next >

Gilead’s Stock Surge: What’s Fueling the Momentum?

November 07, 2024

Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth.

Via MarketBeat

Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript ↗

November 06, 2024

GILD earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales ↗

November 06, 2024

The company also raised its earnings and sales guidance for the year.

Via Investor's Business Daily

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

November 06, 2024

Via Benzinga

Gilead Sciences's Earnings: A Preview ↗

November 05, 2024

Via Benzinga

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required ↗

November 04, 2024

A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.

Via Talk Markets

Peering Into Gilead Sciences's Recent Short Interest ↗

October 21, 2024

Via Benzinga

Evaluating Gilead Sciences: Insights From 15 Financial Analysts ↗

October 21, 2024

Via Benzinga

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

October 17, 2024

Via Benzinga

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗

October 30, 2024

Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks ↗

October 21, 2024

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success...

Via Benzinga

Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 21, 2024

Via Benzinga

Will GILEAD SCIENCES INC breakout? ↗

October 14, 2024

Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC.

Via Chartmill

Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights ↗

October 04, 2024

Via Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today ↗

October 01, 2024

Via Benzinga

This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

October 21, 2024

Via Benzinga

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗

October 18, 2024

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...

Via Benzinga

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 17, 2024

Via Benzinga

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Biotech Stocks Poised For Another Big Move In Q4 ↗

October 07, 2024

The healthcare sector can be a safe haven if volatility increases.

Via Talk Markets

News Is Noise ↗

September 23, 2024

Via Talk Markets

Gilead Sciences Unusual Options Activity For September 20 ↗

September 20, 2024

Via Benzinga

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion' ↗

October 07, 2024

Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.

Via Benzinga

Topics Artificial Intelligence Stocks

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

Top 4 Health Care Stocks That May Keep You Up At Night ↗

September 24, 2024

Via Benzinga

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles ↗

September 23, 2024

Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining...

Via Benzinga

Topics Product Recall

AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug ↗

September 23, 2024

The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.

Via Investor's Business Daily

3 Dirt Cheap Stocks to Buy Right Now ↗

September 21, 2024

Bargain hunters should love these great stocks.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.